Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients

被引:112
作者
Amin, Alpesh N. [1 ]
Varker, Helen [2 ]
Princic, Nicole [2 ]
Lin, Jay [3 ]
Thompson, Stephen [4 ]
Johnston, Stephen [2 ]
机构
[1] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA
[2] Thomson Reuters, Washington, DC USA
[3] Novosys Hlth, Flemington, NY USA
[4] Sanofi Aventis, Bridgewater, NJ USA
关键词
DEEP-VEIN THROMBOSIS; PULMONARY-EMBOLISM; PREVENTION; PLACEBO; PROPHYLAXIS; SAFETY; RATES;
D O I
10.1002/jhm.1002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Patients hospitalized for medical illness are at increased risk of venous thromboembolism (VTE), but the duration of risk is not well understood. OBJECTIVE: To assess incidence and time course of symptomatic VTE following hospitalization for medical illness in a large, real-world patient population. DESIGN: Data were extracted from the Thomson Reuters MarketScan VR Inpatient Drug Link File. PATIENTS: Those hospitalized with cancer, heart failure, severe lung disease, or infectious disease from 2005 to 2008. MEASUREMENTS: The cumulative VTE risk over 180 days after admission was calculated using Kaplan-Meier analysis. VTE hazard was calculated on a daily basis and smoothed through LOESS regression. RESULTS: The analysis included 11,139 medically ill patients, 46.7% and 8.8% of whom received pharmacological thromboprophylaxis during hospitalization and after discharge, respectively. The mean duration of prophylaxis during hospitalization was 5.0 days. Of the 11,139 patients, 366 (3.3%) experienced a symptomatic VTE event. VTE events were most frequent during days 0-9 (97 events), followed by days 10-19 (82 events). The mean length of hospital stay was 5.3 days, and 56.6% of all VTE events occurred after discharge. VTE hazard peaked at day 8, with 1.05 events per 1000 person-days. CONCLUSIONS: The time course of VTE in medical patients shows that risk of symptomatic VTE is highest during the first 19 days after hospital admission, and extends into the period after discharge. Future research is warranted to investigate risks and benefits of reducing the incidence of VTE after discharge, including the role of improving thromboprophylaxis practices in the inpatient setting and extending thromboprophylaxis after hospitalization. Journal of Hospital Medicine 2012; 7: 231-238. (C) 2011 Society of Hospital Medicine
引用
收藏
页码:231 / 238
页数:8
相关论文
共 21 条
  • [1] American Hospital Association, 2009, FACT FACTS US HOSP
  • [2] American Hospital Association, 2009, AHA ANN SURV HOSP DA
  • [3] American Society for Healthcare Engineering of the American Hospital Association, 2009, OV HOSP MARK
  • [4] Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start)
    Amin, A.
    Spyropoulos, A. C.
    Dobesh, P.
    Shorr, A.
    Hussein, M.
    Mozaffari, E.
    Benner, J. S.
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2010, 29 (03) : 326 - 339
  • [5] Amin Alpesh, 2010, Hosp Pract (1995), V38, P17
  • [6] Amin Alpesh N, 2009, J Hosp Med, V4, pE15, DOI 10.1002/jhm.526
  • [7] Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients The ENDORSE Global Survey
    Bergmann, Jean-Francois
    Cohen, Alexander T.
    Tapson, Victor F.
    Goldhaber, Samuel Z.
    Kakkar, Ajay K.
    Deslandes, Bruno
    Huang, Wei
    Anderson, Frederick A., Jr.
    Cherfi, Lyes
    Ammour, Dehbia
    Bentakouk, Cherif
    Bourenane, Razika
    Grainat, Nadia
    Maarouf, Abderahmane
    Sissaoui, Abdelhak
    Gallus, Alexander
    Ayyar, Venkatraman
    Crimmins, Denis
    Gan, Eng
    McRae, Simon
    Seldon, Michael
    Singh, Bhuwan
    Siddiqui, F. M.
    Moula, Kaniz
    Nawaz, Taimor
    Nazimuddin, Khwaja
    Rahman, Saiyeedur
    Sarker, Shyamal
    Rocha, Ana
    Brandao, Carlos
    Costa, Jose
    Macedo, Alex
    Marino, Roberto
    Menezes, Paulo
    Oigman, Wille
    Paiva, Marcelo
    Pantoja, Joao
    Rocha, Ana
    Schramm, Edgar
    Tandeitnik, Liane
    Timi, Jorge
    Staikov, Ivan
    Benov, Haralambi
    Borisov, Stefan Dimitrov
    Lalov, Anton
    Mirazchijski, Boyko
    Postadziyan, Arman
    Sokolov, Krassimir
    Statelov, Evgenii
    Stefanov, Chavdar
    [J]. THROMBOSIS AND HAEMOSTASIS, 2010, 103 (04) : 736 - 748
  • [8] Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial
    Cohen, AT
    Davidson, BL
    Gallus, AS
    Lassen, MR
    Prins, MH
    Tomkowski, W
    Turpie, AGG
    Egberts, JFM
    Lensing, AWA
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7537): : 325 - 327
  • [9] Prevention of venous thromboembolism
    Geerts, William H.
    Bergqvist, David
    Pineo, Graham F.
    Heit, John A.
    Samama, Charles M.
    Lassen, Michael R.
    Colwell, Clifford W.
    [J]. CHEST, 2008, 133 (06) : 381S - 453S
  • [10] *HCUP, 2008, HCUP NIS REL REP